基于转录组测序探究C-MET表达在非小细胞肺癌中的免疫调控机制

doi:10.3969/j.issn.1006-5725.2024.01.002

Abstract

Abstract:

Objective To analyze the immune regulation mechanism of C-MET expression in non-small cell lung cancer by transcriptome sequencing technology. Methods The C-MET expression of lung adenocarcinoma cell line （H1993） and lung squamous cell carcinoma cell line （EBC-1） with high C-MET expression was silenced using siRNA molecular interference technology. The differentially expressed genes （DEGs） before and after C-MET silencing were detected using transcriptome sequencing technology. The signal pathways and related genes of the immune microenvironment in which C-MET may participate in regulation were excavated through bioinformatics analysis. Finally， the co-culture technique of human immune cells with H1993 and EBC-1 was used to verify the effect of C-MET on immune factors such as INF-γ， INF-β and CXCL-10. Results We detected 505 DEGs in total using transcriptome sequencing.There were 38 differentially expressed genes in the C-MET regulation group before and after H1993， 24 upregulated differentially expressed genes， and 14 downregulated differentially expressed genes， respectively. There are a total of 467 differentially expressed genes in the C-MET regulation group of EBC-1， 347 upregulated differentially expressed genes， and 121 downregulated differentially expressed genes， respectively. KEGG analysis of differential genes suggested that C-MET expression might participate in the regulation of immune cell regulatory factors through the IL-17 signaling pathway， white blood cell differentiation， cytokine receptor activity， cell cycle， cytokine receptor activity， and cytokine-cytokine receptor interaction. The effect of C-MET on immune factor secretion was verified using the co-culture technique of lung cancer cells and human immune cells， and the results of Rt-qPCR assay suggested，the mRNA transcriptional level of INF-γ in PBMC co-cultured with the C-MET high expression group was 77 times that of the low expression group， and the mRNA transcriptional level of CXCL-10 was 1.6 times that of the low expression group. The mRNA transcriptional level of INF--β was twice as high as that of the low expression group. Conclusion C-MET expression may participate in the regulation of tumor surrounding immune microenvironment through IL-17 signaling pathway， leukocyte differentiation， and cytokine receptor activity pathway.

Key words: non-small cell lung cancer, C-MET, immune microenvironment, expression profile sequencing

CLC Number:

R734.2

Yue XU,Yanbin ZHANG,Shan. SU. RNA sequencing⁃based research on the immune regulation mechanism of C⁃MET in lung cancer[J]. The Journal of Practical Medicine, 2024, 40(1): 7-12.

Figures/Tables 7

Fig.1

Tab.1

Tab.2

Fig.2

Fig.3

Fig.4

Fig.5

References 21

1	XIA C， DONG X， LI H， et al. Cancer statistics in China and United States， 2022： profiles， trends， and determinants ［J］. Chin Med J （Engl），2022，135（5）：584-590.
2	SIEGEL R L， MILLER K D， WAGLE N S， et al. Cancer statistics， 2023［J］. CA Cancer J Clin， 2023，73（1）：17-48.
3	SAIGI M， ALBURQUERQUE-BEJAR J J， LEER-FLORIN A MC， et al. MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer［J］. Clin Cancer Res，2018，24（18）：4579-4587.
4	ZHANG Y， YANG Q， ZENG X， et al. MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING［J］. Cancer Discov， 2021，11（11）：2726-2737.
5	BENKHOUCHA M， MOLNARFI N， KAYA G， et al. Identification of a novel population of highly cytotoxic c-Met-expressing CD8（+） T lymphocytes［J］. EMBO Rep， 2017，18（9）：1545-1558.
6	YOSHIMURA K， INOUE Y， TSUCHIYA K， et al. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer［J］. Lung cancer， 2020，141：21-31.
7	YOSHIDA R， SAIGI M， TANI T， et al. MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer［J］. Cancer Res， 2022，82（21）：4079-4092.
8	EDWARDS S C， HEDLEY A， HOEVENAAR W H M， et al. PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A-producing γδ T cells［J］. J Exp Med， 2023，220（2）：e20211431.
9	GU C， WU L， LI X. IL-17 family： cytokines， receptors and signaling［J］. Cytokine， 2013，64（2）：477-485.
10	BERRY S P D， DOSSOU C， KASHIF A， et al. The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases［J］. Int Immunopharmacol， 2022，PMID：. pmid: 34863654
11	PATIN E C， SOULARD D， FLEURY S， et al. Type I IFN Receptor Signaling Controls IL7-Dependent Accumulation and Activity of Protumoral IL17A-Producing γδT Cells in Breast Cancer［J］. Cancer Res， 2018，78（1）：195-204.
12	ZHIZHU ZHANG， RICHMOND ANN， CHI YAN. Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer［J］. Int J Mol Sci，2022，23（13）：7353.
13	ANTONELLI A， FERRARI S M， GIUGGIOLI D， et al. Chemokine （C-X-C motif） ligand （CXCL）10 in autoimmune diseases［J］. Autoimmun Rev， 2014，13（3）：272-280.
14	SCIASCIA S， BERTOLACCINI M L， BALDOVINO S， et al. Central nervous system involvement in systemic lupus erythematosus： Overview on classification criteria［J］. Autoimmun Rev， 2013，12（3）：426-429.
15	JORGOVANOVIC D， SONG M， WANG L， et al. Roles of IFN-γin tumor progression and regression： a review［J］. Biomark Res，2020，8：49.
16	GAO Y， YANG J， CAI Y， et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling［J］. Int J Cancer， 2018，143（4）：931-943.
17	XU Y H， LI Z L， QIU S F. IFN-γ Induces Gastric Cancer Cell Proliferation and Metastasis Through Upregulation of Integrin β3-Mediated NF-κB Signaling［J］. Transl Oncol， 2018，11（1）：182-192.
18	FANG C， WENG T， HU S， et al. IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells［J］. Oncoimmunology， 2021，10（1）：1962591.
19	FLIES A S， LYONS A B， CORCORAN L M， et al. PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment［J］. Front Immunol， 2016，7：581.
20	AYERS M， LUNCEFORD J， NEBOZHYN M， et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade［Z］. J Clin Invest， 2017： 127， 2930-2940.
21	DANGAJ D， BRUAND M， GRIMM A J， et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors［J］. CANCER CELL， 2019，35（6）：885-900.

基因名称	log₂FC	P值
DLX4	1.405	< 0.05
DDIT3	1.087	< 0.001
IRF5	1.145	< 0.01
EGR1	-2.280	< 0.001
RORC	1.196	< 0.001
ELF3	1.332	< 0.001
AFF1	1.311	< 0.001
ESX1	-1.622	< 0.01
ETV1	-1.915	< 0.001
ETV4	-1.585	< 0.001

基因名称	log₂FC	P值
PROX2	6.993	< 0.001
ZSCAN4	6.716	< 0.001
ZFP2	5.731	< 0.001
ZEB2	5.716	< 0.01
TBX1	5.261	< 0.01
ZNF880	5.100	< 0.01
TUB	4.898	< 0.001
SIM1	4.836	< 0.05
GATA1	4.814	< 0.05
ZNF410	4.708	< 0.01

[1]	Xinpan LI,Yi FANG,Jun QIU. Predictive value of CD3⁺/CD4⁺T lymphocyte level and neutrophil to lymphocyte ratio in radiation pneumonia [J]. The Journal of Practical Medicine, 2024, 40(20): 2923-2928.
[2]	Xueyan HU,Fanliang MENG,Juanjuan. DONG. Prognostic analysis of patients with bone metastases from primary non-small cell lung cancer with different pathologic staging [J]. The Journal of Practical Medicine, 2024, 40(16): 2316-2325.
[3]	Shengfang YUAN,Bu WANG,Baoli XIANG,Jianqing ZHAO,Jingjing SHEN,Zhihua. ZHANG. Prediction of immune therapy efficacy and prognosis for advanced non-small cell lung cancer using peripheral blood circulation tumor DNA [J]. The Journal of Practical Medicine, 2024, 40(15): 2110-2115.
[4]	Yuting LI,Qilu YAN,Qibin. SONG. Molecular basis of variability in EGFR⁃targeted therapy response in non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2024, 40(15): 2166-2171.
[5]	Ruiwen CHENG,Ruobing HAO,Ping LI,Kun ZHANG,Liping DENG,Yaheng CAO,Lin SU,Hongrong. SHEN. Clinical efficacy of CalliSpheres drug⁃loaded microspheres versus blank microspheres in the treatment of advanced non⁃small cell lung cancer by transarterial chemoembolization [J]. The Journal of Practical Medicine, 2024, 40(1): 32-37.
[6]	Mingxing LI,Zhuoxian LI,Kangmei LI,Xiurong CHEN,Yanping ZHOU,Yulin HUANG,Lin BAI,Zhanshuai WU,Meng XIA,Guozhen. HE. Role of hepatocyte growth factor （HGF）/c⁃Met signaling pathway in early follicular development in mice [J]. The Journal of Practical Medicine, 2023, 39(20): 2566-2571.
[7]	YU Li′na, YAN Shengguang, XIE Dan, GAO Sheng, YE Zheng, CHEN Ziren, WANG Zihua, OUYANG Shi.. Mechanisms for improving the immune microenvironment of autoimmune hepatitis by umbilical cord mes⁃ enchymal stem cells [J]. The Journal of Practical Medicine, 2023, 39(12): 1466-1472.

RNA sequencing⁃based research on the immune regulation mechanism of C⁃MET in lung cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 21

Related Articles 7

Recommended Articles

Metrics

Comments